Insulin Glargine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Insulin Glargine: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin glargine is a long-acting basal insulin analog originally used to treat Type 1 and Type 2 diabetes mellitus. The TxGNN model predicts a possible link to Autoimmune Oophoritis, but this prediction currently has no supporting clinical trials or literature, and the underlying rationale describes only an indirect, disease-co-occurrence relationship rather than a treatment mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes mellitus (Type 1 and Type 2) |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.88% (model rank 1777) |
| Evidence Level | L5 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in this evidence pack. Based on known pharmacology, insulin glargine is a long-acting recombinant human insulin analog that provides basal glycemic control by activating the insulin receptor; its efficacy in diabetes mellitus is well established.
The proposed link to autoimmune oophoritis, however, is not a pharmacological treatment relationship. Autoimmune oophoritis is a component of autoimmune polyendocrine syndrome (APS) and can co-occur with Type 1 diabetes, but there is no direct mechanistic pathway by which insulin would treat ovarian autoimmune inflammation. The model's own rationale explicitly describes this as a "knowledge-graph proximity effect" driven by shared autoimmune/endocrine disease nodes, rather than a genuine drug-disease treatment signal.
Given this, the prediction should be interpreted as a hypothesis-generating signal only — it reflects disease co-occurrence patterns learned by the model, not evidence of therapeutic benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Insulin glargine currently has no registered marketing authorizations in Finland under this evidence pack (0 licenses on file; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/Fimea package insert warnings, contraindications, and drug interaction data are flagged as a blocking data gap (DG001) in this evidence pack and could not be retrieved for this evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (autoimmune oophoritis) has an L5 evidence level — a model prediction only, with zero supporting clinical trials or literature, and the rationale explicitly identifies the link as an indirect co-occurrence artifact rather than a treatment mechanism. This does not meet the threshold to proceed.
To proceed, the following is needed:
- Fimea/TFDA package insert data (warnings, contraindications) — currently a blocking gap (DG001)
- Confirmed mechanism of action data (DG002)
- Targeted literature/trial search specifically on insulin and autoimmune oophoritis or APS-related ovarian failure to test whether any indirect supportive evidence exists
- Consider re-evaluating pancreatic agenesis (rank 6 in this candidate set) as an alternative direction: it carries a stronger mechanistic rationale (congenital β-cell absence requiring exogenous insulin) and has 6 associated literature records, though none directly studies this rare condition — it is currently staged at S1 with a "Research Question" recommendation rather than "Hold."
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.